Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

## Patient: Patient, Example

| | |
|---|---|
| **DOB** | 2/1/2002 |
| **Gender:** | Unknown |
| **Patient Identifiers:** | 01234567890ABCD, 012345 |
| **Visit Number (FIN):** | 01234567890ABCD |
| **Collection Date:** | 00/00/0000 00:00 |

## Paraneoplastic Reflexive Panel

ARUP test code 3002929

| | | | |
|---|---|---|---|
| Neuronal Antibody (Amphiphysin) | **Positive** | * | (Ref Interval: Negative) |

INTERPRETIVE INFORMATION: Amphiphysin Antibody, IgG

Amphiphysin antibody is present in about 5 percent of patients with stiff-person syndrome and is found variably in other causes of paraneoplastic neurological syndrome (PNS). Amphiphysin antibody is mainly associated with small-cell lung cancer and breast tumors.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

| | | | |
|---|---|---|---|
| Purkinje Cell/Neuronal Nuclear IgG Scrn | **ANNA Detected** | * | (Ref Interval: None Detected) |

Antibodies detected, therefore IFA titer and Immunoblot testing to be performed.

INTERPRETIVE INFORMATION: Purkinje Cell/Neuronal Nuclear IgG Scrn

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

| | | | |
|---|---|---|---|
| CV2.1 Ab IgG CBA-IFA Screen, Serum | **Detected** | * | (Ref Interval: <1:10) |

CV2.1 Antibody, IgG is detected. Titer results to follow. Additional charges apply.

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: CV2.1 Ab IgG CBA-IFA Screen, Serum

CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CV2.1 transfected cell lines for the detection and semiquantification of the CV2.1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

| | | | |
|---|---|---|---|
| SOX1 Antibody, IgG by Immunoblot, Serum | **Positive** | * | **(Ref Interval: Negative)** |

INTERPRETIVE INFORMATION: SOX1 Antibody, IgG by Immunoblot, Serum
SOX1 antibody is detected in patients with Lambert-Eaton myasthenic syndrome (LEMS) and in patients with paraneoplastic cerebellar degeneration (PCD), paraneoplastic and nonparaneoplastic neuropathy. SOX1 antibody is associated with small cell lung cancer. A negative test result does not rule out a diagnosis of LEMS or other causes of paraneoplastic neurological syndrome.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

## Neuronal Nuclear Antibody (ANNA) IFA Titer, IgG (Do Not Use - Please Order (2007961) Paraneoplastic Antibodies (PCCA/ANNA) by IFA with Reflex to Titer and Immunoblot)

ARUP test code 0050892

| | | | |
|---|---|---|---|
| Neuronal Nuclear Ab (ANNA) IFA Titer IgG | 1:40 | * | **(Ref Interval: <1:10)** |

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (ANNA) IFA Titer IgG

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

## CV2.1 Antibody Titer, IgG by CBA-IFA, Serum (Reflex for 2013956 CV2.1SCRN Not orderable by clients)

ARUP test code 2013957

| | | | |
|---|---|---|---|
| CV2.1 Ab IgG CBA-IFA Titer, Serum | 1:20 | * | **(Ref Interval: <1:10)** |

**H=High, L=Low, *=Abnormal, C=Critical**

INTERPRETIVE INFORMATION: CV2.1 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

## Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot, Serum

ARUP test code 3002917

| | | | |
|---|---|---|---|
| Neuronal Nuclear Ab (Hu) IgG, IB, Serum | **Positive** | * | **(Ref Interval: Negative)** |

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab IgG, Immunoblot, Ser
This test detects IgG antineuronal antibodies to Hu, Ri, Yo and Tr (DNER) antigens.

Antineuronal antibodies serve as markers that aid in discriminating between a true paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-Hu (antineuronal nuclear antibody, type I) is associated with small-cell lung cancer. Anti-Ri (antineuronal nuclear antibody, type II) is associated with neuroblastoma in children and with fallopian tube and breast cancer in adults. Anti-Yo (anti-Purkinje cell cytoplasmic antibody) is associated with ovarian and breast cancer. Anti-Tr(DNER) is associated with Hodgkin's lymphoma.

The presence of one or more of these antineuronal antibodies supports a clinical diagnosis of PND and should lead to a focused search for the underlying neoplasm.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

| | | | |
|---|---|---|---|
| Neuronal Nuclear Ab (Ri) IgG, IB, Serum | **Positive** | * | **(Ref Interval: Negative)** |

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Ri) IgG, IB, Serum
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

| | | | |
|---|---|---|---|
| Neuronal Nuclear Ab (Yo) IgG, IB, Serum | **Positive** | * | **(Ref Interval: Negative)** |

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (Yo) IgG, IB, Serum
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

| | | | |
|---|---|---|---|
| Neuronal Nuclear Ab (TR/DNER) IgG, IB | **Positive** | * | **(Ref Interval: Negative)** |

**H=High, L=Low, *=Abnormal, C=Critical**

INTERPRETIVE INFORMATION: Neuronal Nuclear Ab (TR/DNER) IgG, IB
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

| Procedure | Accession | Collected | Received | Verified/Reported |
|---|---|---|---|---|
| Neuronal Antibody (Amphiphysin) | 23-241-112442 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Purkinje Cell/Neuronal Nuclear IgG Scrn | 23-241-112442 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Neuronal Nuclear Ab (ANNA) IFA Titer IgG | 23-241-112442 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| CV2.1 Ab IgG CBA-IFA Screen, Serum | 23-241-112442 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| CV2.1 Ab IgG CBA-IFA Titer, Serum | 23-241-112442 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Neuronal Nuclear Ab (Hu) IgG, IB, Serum | 23-241-112442 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Neuronal Nuclear Ab (Ri) IgG, IB, Serum | 23-241-112442 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Neuronal Nuclear Ab (Yo) IgG, IB, Serum | 23-241-112442 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Neuronal Nuclear Ab (TR/DNER) IgG, IB | 23-241-112442 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| SOX1 Antibody, IgG by Immunoblot, Serum | 23-241-112442 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |

END OF CHART

**H=High, L=Low, *=Abnormal, C=Critical**